Mirati Therapeutics To Present Preclinical Data At 2016 American Association For Cancer Research Annual Meeting

SAN DIEGO, March 24, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced it will present preclinical data on two of its three oncology therapies currently in development. Data on glesatinib (MGCD265), its tyrosine kinase inhibitor targeting MET and Axl; and mocetinostat (MGCD103), its spectrum-selective HDAC inhibitor, will be presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting to be held in New Orleans, LA from April 16-20, 2016.

Preclinical work from both programs will be highlighted in the following mini-symposium presentation and poster session:

- **Abstract No. 2642**: "Evaluation of the mechanism of MET-dependent cellular transformation and potent cytoreductive activity of MGCD265 in novel MET exon 14 mutation positive cancer models"
  **Presenting Author**: Lars Engstrom, Senior Scientist, Mirati Therapeutics
  **Mini-Symposium Session**: Hitting the Target Harder: Preclinical Development of Potent and Selective Inhibitors
  **Presentation Time/Location**: Monday, April 18, 2016 from 3:20 - 3:35 p.m. CT; New Orleans Theater A, Morial Convention Center

- **Abstract No. 4021**: "The class I HDAC inhibitor, mocetinostat, induces expression of PD-L1 and tumor antigen presentation machinery and modifies tumor immune cellular subsets providing a rationale for immune checkpoint inhibitor combinations"
  **Presenting Author**: David Briere, Principal Scientist, Mirati Therapeutics
  **Poster Session**: Mechanisms and Applications of Immune-based Therapies
  **Time/Location**: Tuesday, April 19, 2016 from 1:00 - 5:00 p.m. CT; Section 27, Poster Board 4

About Mirati Therapeutics
Mirati Therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. Mirati’s approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. The Mirati team uses a blueprint - proven by their prior work - for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. Mirati is advancing three drug candidates through clinical development for multiple oncology indications. More information is available at [www.mirati.com](http://www.mirati.com).


SOURCE Mirati Therapeutics, Inc.